Ivermectin helped people RECOVER FASTER from COVID-19 infections, study finds

03/14/2024 / By Ava Grace

A study has once again attested to the ability of anti-parasitic drug ivermectin against the Wuhan coronavirus (COVID-19), with the said paper finding that it helped people recover faster from infection.

The study published Feb. 29 in the Journal of Infection (JoI) involved 8,811 participants who tested positive for COVID-19 in the so-called PRINCIPLE Trial. Of this number, 2,157 were given ivermectin as treatment. The other 3,398 participants received other treatments, while the remaining 3,256 received the usual standard of care for COVID-19 infection.

The study was conducted from June 23, 2021 to July 1, 2022. It ultimately found that the ivermectin recipients had a shorter recovery period – a median of two days – compared to the other two groups. Those who received ivermectin were also less likely to be hospitalized or die, with 1.6 percent of participants in this group suffering from these outcomes. In contrast, four percent of the usual care group died of COVID-19, if not hospitalized.

Moreover, ivermectin recipients also enjoyed a reduction of severe symptoms and sustained recovery. Despite this promising discovery, the study authors absurdly discouraged the use of ivermectin to treat COVID-19. (Related: Ivermectin is trending again… New scientific paper released exposing “miracle drug.”)

“Ivermectin for COVID-19 is unlikely to provide clinically meaningful improvement for recovery, hospital admissions or longer-term outcomes. Further trials of ivermectin for SARS-CoV-2 infection in vaccinated community populations appear unwarranted,” they wrote in the study’s interpretation section.

They ultimately concluded: “The results from our trial … support the position that ivermectin should not be used to treat SARS-CoV-2 infection in the community in high-income countries with a largely vaccinated population. We consider that additional studies of ivermectin in this population should not be a priority for research.”

According to the Epoch Times, the study authors involved in the PRINCIPLE Trial divulged conflicts of interest in their paper. One co-author received grants from pharmaceutical companies including AstraZeneca, while other disclosed receiving grants from the University of Oxford. Incidentally, the university was instrumental in developing AstraZeneca’s COVID-19 vaccine that uses an adenovirus vector.

Study wrongly downplayed how ivermectin improved recovery from COVID-19

Dr. Christopher Butler, the study’s corresponding author, said: “Ivermectin is readily available globally [and] has been in wide use for many other infectious conditions. It’s a well-known medicine with a good safety profile and because of the early promising results in some studies, it is already being widely used to treat COVID-19 in several countries.

However, the decision of Butler and his co-authors to smear ivermectin in their study despite acknowledging its effects against SARS-CoV-2 has left many scratching their heads. This led to American physician Dr. Pierre Kory to accuse the authors of “setting a new record for ivermectin research fraud.” According to him, Butler and his colleagues wrongly downplayed how ivermectin improved recovery from COVID-19.

“PRINCIPLE was a profoundly positive study that was instead analyzed and written up as a negative one,” Kory wrote in a March 5 piece on his Substack. The co-founder and president of the Front Line COVID-19 Critical Care Alliance (FLCCC) has long promoted ivermectin as a COVID-19 treatment over the deadly COVID-19 injections.

“The millions of patients and doctors around the world who know how effective and safe of an antiviral [ivermectin] is will continue to use it for COVID-19, flu, Disease X and beyond.”

Watch Dr. Pierre Kory testify to the effectiveness of ivermectin against COVID-19, citing a study that involved more than 500,000 participants to back up his testimony.

This video is from the GalacticStorm channel on Brighteon.com.